Mesoblast (NASDAQ:MESO) Shares Gap Up – Still a Buy?

Mesoblast Limited (NASDAQ:MESO) gapped up before the market opened on Tuesday . The stock had previously closed at $17.30, but opened at $18.54. Mesoblast shares last traded at $18.51, with a volume of 45,094 shares trading hands.

Wall Street Analyst Weigh In

MESO has been the topic of several analyst reports. Piper Sandler lifted their price objective on Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a report on Thursday, December 19th. Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $13.50.

Mesoblast Stock Performance

The business’s fifty day simple moving average is $14.51 and its 200-day simple moving average is $10.06. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18.

Institutional Trading of Mesoblast

Several large investors have recently modified their holdings of MESO. Jane Street Group LLC increased its position in Mesoblast by 46.4% during the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after purchasing an additional 26,959 shares during the period. Marshall Wace LLP bought a new stake in shares of Mesoblast during the 2nd quarter valued at about $562,000. Lazari Capital Management Inc. boosted its stake in shares of Mesoblast by 6.6% during the 2nd quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock valued at $364,000 after purchasing an additional 3,300 shares in the last quarter. XY Capital Ltd purchased a new position in shares of Mesoblast during the third quarter valued at about $244,000. Finally, Creative Planning bought a new position in Mesoblast in the third quarter worth about $147,000. 1.43% of the stock is owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.